Zotefoams plc
("Zotefoams", or the "Group")
Preliminary results presentation
17 March 2025 - Zotefoams, a world leader in supercritical foams, is pleased to announce that Ronan Cox, Group CEO, and Gary McGrath, Group CFO, will provide a live presentation relating to the 2024 Preliminary Results via Investor Meet Company on 24 Mar 2025, 13:30 GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 23 Mar 2025, 09:00 GMT, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet ZOTEFOAMS PLC via: https://www.investormeetcompany.com/zotefoams-plc/register-investor
Investors who already follow ZOTEFOAMS PLC on the Investor Meet Company platform will automatically be invited.
- Ends -
Enquiries:
| Zotefoams plc | +44 (0) 208 664 1600 |
| Ronan Cox, Group CEO | |
| Gary McGrath, Group CFO | |
About Zotefoams plc
Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications.
Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA, Stilling, Denmark (microcellular foam technology) and Jiangsu Province, China (T-FIT).
AZOTE®, ZOTEK®, and T-FIT® are registered trademarks of Zotefoams plc.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
